Eli Lilly and Company (Lilly) has reported a net income of $4.4bn, or $4.88 per diluted share, for the fourth quarter ended 31 December 2024, compared to $2.19bn, or $2.42 per diluted share, for the same quarter in 2023.
The pharmaceutical company’s net income for Q4 2024 increased compared to $970.3m for the preceding quarter, the third quarter of 2024 (Q3 2024)
Lilly reported a total revenue of $13.53bn for Q4 2024, a 45% rise compared to $9.35bn for the same quarter in 2023 and an 18% increase compared to $11.43bn for Q3 2024.
The US drugmaker reported an operating income of $5.15bn for Q4 2024, compared to $2.38bn for the respective quarter in the previous year.
The company reported an income before tax of $5.04bn for Q4 2024, compared to $2.5bn for the same period in 2023.
Lilly chair and CEO David Ricks said: “We had major data readouts for tirzepatide in treating a chronic disease associated with obesity, invested billions more in expanding our manufacturing capacity and launched Kisunla and Ebglyss, important drivers of our long-term balanced growth outlook.
“We enter 2025 with tremendous momentum and look forward to strong financial performance and several important Phase 3 readouts which, if positive, will further accelerate our long-term growth.”
Lilly reported a net income of $10.59bn, or $ 11.71 per diluted share, for the full year 2024, compared to $5.24bn, or $ 5.80 per diluted share, for the full year 2023.
The pharmaceutical company reported a total revenue of $45.04bn for the full year 2024, a 32% rise compared to $34.12bn for the full year 2023.
Lilly reported an operating income of $12.89bn for the full year 2024, a 100% increase compared to $6.45bn for the full year 2023.
The US-based company reported an income before tax of $12.68 for the full year 2024, a 93% rise compared to $6.55bn for the full year 2023.
